http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2695167-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a60559e5784c59f0119d0cf1c3455f2b |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-6615 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-232 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-661 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 |
filingDate | 2007-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e9c25f3887ddcbf1fd236eb66869d1c |
publicationDate | 2008-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CA-2695167-A1 |
titleOfInvention | Methods for the treatment of elevated cholesterol levels |
abstract | Use of a one or more of the following compounds: DHAP;1-acyl-DHAP;1-alkyl-DHAP; 1-alkyl-G3P; 1-alkyl, 2-acyl-G3P; 1-alkyl, 2-acyl-glycerol; 1-alkyl, 2-acyl-GPE, 1-alkyl, diacyl glycerol (sn-1=16:0, sn-2=DHA, sn-3=DHA) (sn-1 position has an alkyl ether bond, sn-2 and sn-3 positions have acyl bonds); 1-alkyl diacyl glycerol (sn-1=16:0, sn-2=18:1, sn-3=18:1) (sn-1 position has an alkyl ether bond, sn-2 and sn-3 positions have acyl bonds); triacyl glycerol (sn-1=16:0, sn-2=DHA, sn-3=DHA) (all three positions have acyl bonds); and triacyl glycerol (sn-1=16:0, sn-2=18:1, sn-3=18:1) (all three positions have acyl bonds), including pharmaceutically acceptable salts thereof, for lowering cholesterol in a patient in need thereof. Also described is the use of an ethanolamine plasmalogen elevating therapeutic agent for the treatment of a subject diagnosed with high cholesterol and decreased levels of one or more ethanolamine plasmalogen. In one particular embodiment the ethanolamine plasmalogen elevating therapeutic agent is: (see formula 5a) |
priorityDate | 2007-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 40.